I’ll spare you the usual hype associated with any publication’s subscription drive. Suffice it to say that Arsalan Arif and I are a little over the moon about the initial response, and we’re in the process of hiring for a few enormously important roles for the team as a result.
The way I had initially envisioned it, I had thought that the big push would come around the individual subscribers. It was Arsalan, the platform expert here, who blew right past that and set up a compelling case for our Enterprise subscription for companies. Not only did the Enterprise subs provide the lion’s share of the first round of cash, it’s also been driving rapid growth in overall readership as companies spread the word about Endpoints News and their involvement as a paid subscriber.
Arsalan is the tacit tech chief here — I remain largely illiterate in that field — and I can’t thank him enough for what he’s done. As a result of his work, most of the largest biopharmas in the world are now on board, along with a lengthy list of biotechs, and we’re working on the rest.
Now that we’ve completed the first leg of the Enterprise drive, though, I did want to make another pitch to you individual subscribers out there who want to support the mission at Endpoints News. When you don’t have billionaires writing checks to cover operations, this remains a key part of our plan for ramping up the editorial and sales teams.
Without your help, and time and attention, we would be looking at an extremely long runway to get the group in place.
With your help now, we can stick with the extremely short — and fast — track we’ve laid. You can check out the subscription link here below.
And thank you.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,300+ biopharma pros who read Endpoints News by email every day.Free Subscription